(NP (-LRB- -LCB-) (NP (JJ Regulatory) (NN effect)) (PP (IN of) (NP (NN insulin))) (PP (IN on) (NP (NP (NN glucocorticoid) (NN receptor)) (PP (IN in) (NP (JJ human) (JJ peripheral) (NNS leukocytes))))) (-RRB- -RCB-))
(S (NP-SBJ-8 (NP (DT The) (JJ regulatory) (NN effect)) (PP (IN of) (NP (NN insulin))) (PP (IN on) (NP (NP (DT the) (JJ specific) (VBG binding) (NN power)) (PP (IN of) (NP (NP (NP (NN glucocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN GR)) (-RRB- -RRB-))) (PP (IN of) (NP (JJ human) (NNS leukocytes)))))))) (VP (VBD was) (VP (VBN assessed) (NP (-NONE- *-8)) (PP (IN by) (NP (NP (DT the) (JJ unoccupied) (NN receptor) (NNS sites)) (ADJP (JJ capable) (PP (IN of) (S (NP-SBJ (-NONE- *)) (VP (VBG combining) (PP (IN with) (NP (NP (NN -LCB-3H-RCB-) (JJ labelled) (NN dexamethasone)) (VP (VBN measured) (NP (-NONE- *)) (PP-TMP (IN at) (NP (NP (QP (CD 3) (CC and) (CD 24)) (NN h)) (PP-TMP (IN after) (NP (NN incubation) (PP (IN with) (NP (NP (JJ various) (NNS concentrations)) (PP (IN of) (NP (NN insulin))) (VP (VBN added) (NP (-NONE- *)) (PP (TO to) (NP (DT the) (NN medium))))))))))))))))))))) (. .))
(S (PP-TMP (IN After) (NP (ADJP (CD 3) (NN h)) (NN incubation))) (NP-SBJ-10 (NP (DT the) (JJ specific) (VBG binding) (NN power)) (PP (IN with) (NP (NN -LCB-3H-RCB-) (NN Dex)))) (VP (VBD was) (VP (VBN decreased) (NP (-NONE- *-10)) (PP (IN by) (NP (NP (NP-COOD (NP (QP (CD 23.3) (CC (- +)) (CD 10.0)) (NP (-NONE- *RNR*-90))) (, ,) (NP (QP (CD 32.2) (CC (- +)) (CD 13.2)) (NP (-NONE- *RNR*-90))) (CC and) (NP (QP (CD 54.3) (CC (- +)) (CD 9.2)) (NP (-NONE- *RNR*-90)))) (NP-90 (NN %))) (PRN (-LRB- -LRB-) (NP (NP-COOD (NP (NP (NN P)) (ADJP (ADJP (JJR greater)) (PP (IN than) (NP (CD 0.05))))) (, ,) (NP (NP (NN P)) (ADJP (ADJP (JJR greater)) (PP (IN than) (NP (CD 0.05))))) (CC and) (NP (NP (NN P)) (ADJP (ADJP (JJR less)) (PP (IN than) (NP (CD 0.01)))))) (SBAR (IN as) (S (NP-SBJ-11 (-NONE- *)) (VP (VBN compared) (NP (-NONE- *-11)) (PP (IN with) (NP (NP (NP (DT the) (NN control) (NN value)) (PP (IN of) (NP (CD 100)))) (PP (IN in) (DT the) (NN absence) (IN of) (NP (NN insulin))))))))) (-RRB- -RRB-)))) (ADVP (RB respectively)) (PP (IN in) (DT the) (NN presence) (IN of) (NP (NP (NP-COOD (NP (NP (CD 20) (NN (L mU))) (PRN (-LRB- -LRB-) (NP (JJ physiological) (NN testing) (NN concentration)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 200) (NN (L mU))) (PRN (-LRB- -LRB-) (NP (JJ physiological) (JJ upper) (NN limit)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 2,000) (NN (L mU))) (PRN (-LRB- -LRB-) (NP (JJ pharmacological) (NN concentration)) (-RRB- -RRB-)))) (NN insulin)) (PP (IN in) (NP (DT the) (NN incubation) (NN medium))))))) (. .))
(S (PP-TMP (IN After) (NP (ADJP (CD 24) (NN h)) (NN incubation))) (NP-SBJ (NP (DT the) (NN decrease)) (PP (IN of) (NP (DT these) (NNS values)))) (VP (VBD increased) (ADVP (RB respectively)) (PP (TO to) (NP (NP-COOD (NP (QP (CD 43.5) (CC (- +)) (CD 19.0))) (, ,) (NP (QP (CD 56.1) (CC (- +)) (CD 20.7))) (CC and) (NP (QP (CD 80.2) (CC (- +)) (CD 15.5)))) (PRN (-LRB- -LRB-) (NP (NP-COOD (NP (NP (NN P)) (ADJP (ADJP (JJR less)) (PP (IN than) (NP (CD 0.05))))) (, ,) (NP (NP (NN P)) (ADJP (ADJP (JJR less)) (PP (IN than) (NP (CD 0.01))))) (CC and) (NP (NP (NN P)) (ADJP (ADJP (JJR less)) (PP (IN than) (NP (CD 0.01)))))) (S (NP-SBJ-92 (-NONE- *)) (VP (VBN compared) (NP (-NONE- *-92)) (PP (IN with) (NP (NN control)))))) (-RRB- -RRB-))))) (. .))
(S (ADVP (RB Thus)) (NP-SBJ (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NN insulin))) (PP (IN on) (NP (DT the) (NN GR) (NN binding) (NN power)))) (VP (VP (VBZ is) (ADJP-PRD (CC both) (ADJP-COOD (ADJP (NP (NN dose-)) (ADJP (-NONE- *?*))) (CC and) (ADJP (JJ time-dependent))))) (, ,) (SBAR (WHNP-12 (WDT which)) (S (NP-SBJ (-NONE- *T*-12)) (ADVP (RB strongly)) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ-13 (NN GR)) (VP (VBZ is) (ADVP (RB tonically)) (VP (VBN controlled) (NP (-NONE- *-13)) (PP (IN by) (NP-LGS (NP (NN insulin) (NN concentration) (NN change)) (PP (IN under) (NP (JJ physiological) (NNS conditions))))))))))))) (. .))
